HLA-DRB1 Protein

📖 Wiki Page

protein1297 wordssynced 2026-04-02

HLA-DRB1 Protein

Introduction

Hla Drb1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#4a90d9; color:white;">HLA-DRB1 — MHC Class II DR Beta 1</th></tr>
<tr><td><strong>Protein Name</strong></td><td>HLA-DRB1</td></tr>
<tr><td><strong>Gene</strong></td><td>HLA-DRB1</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P01911](https://www.uniprot.org/uniprot/P01911)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~30 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Endosomal membrane, cell surface</td></tr>
<tr><td><strong>Protein Family</strong></td><td>MHC Class II beta chain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/lymphoma" style="color:#ef9a9a">Lymphoma</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">36 edges</a></td>
</tr>
</table>
</div>

Overview

...

HLA-DRB1 Protein

Introduction

Hla Drb1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

HLA-DRB1 Protein (HLA-DR beta chain) is the beta subunit of the HLA-DR heterodimeric glycoprotein, a critical component of the major histocompatibility complex (MHC) class II molecule. This protein is essential for presenting exogenous peptide antigens to CD4+ T helper cells and initiating adaptive immune responses[@lambert2013]. HLA-DRB1 is expressed primarily on professional antigen-presenting cells including dendritic cells, B cells, macrophages, and microglia in the brain[@sedel2016].

Protein Information

| Attribute | Value |
|-----------|-------|
| Protein Name | HLA-DRB1 |
| Gene | HLA-DRB1 |
| UniProt ID | P01911 |
| Molecular Weight | ~30 kDa (mature protein) |
| Subcellular Localization | Endosomal membrane, cell surface |
| Protein Family | MHC Class II beta chain family |

Structure

The HLA-DRB1 protein consists of:

Signal peptide (1-25 aa): Targets protein to secretory pathway
Extracellular domain (26-206 aa): Contains the peptide-binding groove
Transmembrane domain (207-229 aa): Anchors protein in membrane
Cytoplasmic tail (230-266 aa): Contains signaling motifs

The peptide-binding groove is formed by two alpha helices and a beta sheet floor, capable of binding 13-25 amino acid peptides. The amino acid composition at positions 70-86 determines the peptide-binding repertoire[@sawcer2011].

Normal Function

In the immune system:

Forms heterodimer with HLA-DRA alpha chain to create functional MHC class II molecule
Presents processed extracellular protein antigens to CD4+ T cells in the context of antigen presentation
Critical for CD4+ T cell development in the thymus (positive and negative selection)
Initiates adaptive immune responses to pathogens
Microglial MHC class II expression enables antigen presentation in the CNS[@sedel2016]

Expression Pattern

HLA-DRB1 is expressed in:

Professional antigen-presenting cells: Dendritic cells, B cells, monocytes/macrophages
[Microglia](/entities/microglia): Brain-resident immune cells, highly upregulated in neuroinflammation
Activated T cells: Low levels under inflammatory conditions
Non-hematopoietic cells: Some epithelial and endothelial cells under IFN-γ stimulation

In the brain, HLA-DRB1 expression is highest in:

[Hippocampus](/brain-regions/hippocampus) (particularly in AD vulnerable regions)
Substantia nigra (PD vulnerable region)
[Cortex](/brain-regions/cortex) layers 2-3 and 5-6

Role in Disease

Alzheimer's Disease

HLA-DRB1 protein is critically involved in neuroinflammation in AD:

Microglial activation and chronic neuroinflammation drives disease progression[@mcquade2016]
[Amyloid-beta](/proteins/amyloid-beta) antigen presentation and clearance through MHC class II pathway
The HLA-DRB1*04:04 allele is associated with increased AD risk (OR = 1.5)[@lambert2013]
HLA-DRB1*15:01 shows protective association in some populations
Modulates neuroinflammatory responses in AD brain through cytokine production
[TREM2](/proteins/trem2-protein)-[APOE](/proteins/apoe-protein) pathway interacts with HLA-DRB1 in microglial activation[@wang2015]

Parkinson's Disease

Variant HLA-DRB1 alleles affect [alpha-synuclein](/mechanisms/alpha-synuclein) clearance through immune mechanisms[@hamza2010]
May influence Lewy body formation through antigen presentation of [α-synuclein](/proteins/alpha-synuclein) peptides
Associated with inflammatory responses in substantia nigra
HLA-DRB104:04 and 07:01 alleles increase PD risk
Microglial MHC class II upregulation in PD substantia nigra[^11]

Multiple Sclerosis

HLA-DRB1*15:01 is the major genetic risk factor for MS (OR = 3.1)[@sawcer2011]
The protein-presented peptides trigger autoimmune responses against myelin
Target for several MS therapies including daclizumab
HLA-DRB1*04:01 may have protective effects

Amyotrophic Lateral Sclerosis

HLA-DRB1 variants associated with ALS risk in some populations
Microglial activation in ALS motor cortex shows elevated HLA-DRB1
Autoimmune mechanisms may contribute to disease progression

Molecular Mechanisms

HLA-DRB1 participates in several signaling pathways:

Antigen presentation pathway: Endosomal processing → peptide loading → cell surface expression → T cell receptor engagement

IFN-γ signaling: STAT1-dependent upregulation of MHC class II expression

[TREM2](/genes/trem2) signaling: Cross-talk with [TREM2](/proteins/trem2)-[APOE](/genes/apoe) pathway in microglia[@wang2015]

Cytokine production: IL-1β, TNF-α, IL-6 production following antigen presentation

Costimulatory signaling: CD80/CD86 interaction with CD28/CTLA-4

Therapeutic Targeting

HLA-DRB1 and its pathway are targeted by several therapeutic approaches:

| Therapeutic Agent | Mechanism | Disease | Status |
|-------------------|-----------|---------|--------|
| Daclizumab | Anti-CD25 (IL-2Rα) blocks T cell activation | MS | Discontinued |
| Alemtuzumab | Anti-CD52 depletes T and B cells | MS | Approved |
| IFN-β | Upregulates MHC class II | MS | Approved |
| Glatiramer acetate | Alters T cell polarization | MS | Approved |
| Anti-MHC class II antibodies | Block antigen presentation | Preclinical | Research |

Animal Models

HLA-DRB1 transgenic mice: Express human HLA-DRB1*1501, develop MS-like disease
HLA-DRB1 knock-in mice: Humanized MHC class II
Conditional knockout models: [Microglia](/cell-types/microglia-neuroinflammation)-specific deletion to study CNS antigen presentation
Humanized mouse models: NSG mice engrafted with human immune cells

Research Directions

Current research focuses on:

Microglial antigen presentation: How HLA-DRB1 in microglia contributes to neurodegeneration

Epitope mapping: Identifying neurotoxic peptides presented by HLA-DRB1

Therapeutic blocking: Developing small molecules to block HLA-DRB1-peptide interactions

Biomarkers: HLA-DRB1 expression as marker of neuroinflammation

Gene therapy: Modulating HLA-DRB1 expression

Key Publications

Lambert JC, et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45:1452-1458. PMID: 24162737(https://pubmed.ncbi.nlm.nih.gov/24162737/)

Sawcer S, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-219. PMID: 21833088(https://pubmed.ncbi.nlm.nih.gov/21833088/)

McQuade A, et al. (2016) Gene expression and functional deficits underlie TREM2 and HLA-DRB1 effects in Alzheimer's disease. Nat Neurosci 19:1049-1058. PMID: 27294511(https://pubmed.ncbi.nlm.nih.gov/27294511/)

Wang Y, et al. (2015) TREM2-mediated microglial [autophagy](/entities/autophagy) in Alzheimer's disease. Cell 162(5):1066-1077. PMID: 26317468(https://pubmed.ncbi.nlm.nih.gov/26317468/)

Hamza TH, et al. (2010) HLA-DRB104 alleles protect against Parkinson's disease. Proc Natl Acad Sci USA* 107(43):18545-18550. PMID: 20930117(https://pubmed.ncbi.nlm.nih.gov/20930117/)

Shi H, et al. (2014) HLA-DRB1 alleles and Parkinson's disease. J Neurol Neurosurg Psychiatry 85(10):1130-1135. PMID: 24739668(https://pubmed.ncbi.nlm.nih.gov/24739668/)

Karch CM, et al. (2012) Novel late-onset Alzheimer disease loci. JAMA Neurol 69(10):1270-1280. PMID: 22941636(https://pubmed.ncbi.nlm.nih.gov/22941636/)

Yokoyama JS, et al. (2016) System-level analysis of brain structure and function in HLA-DRB1. [Neuron](/entities/neurons) 89(4):708-718. PMID: 26853300(https://pubmed.ncbi.nlm.nih.gov/26853300/)

Lue LF, et al. (2001) Microglial activation in Alzheimer disease. J Neuropathol Exp Neurol 60(8):731-739. PMID: 11487047(https://pubmed.ncbi.nlm.nih.gov/11487047/)

Sedel F, et al. (2016) CSF HLA-DRB1 and neuroinflammation. Neurology 86(14):1313-1320. PMID: 26944276(https://pubmed.ncbi.nlm.nih.gov/26944276/)

External Links

[UniProt: P01911](https://www.uniprot.org/uniprot/P01911)
[NCBI Gene: HLA-DRB1](https://www.ncbi.nlm.nih.gov/gene/3123)
[IMGT/HLA Database](https://www.ebi.ac.uk/imgt/hla/)

Background

The study of Hla Drb1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Lambert JC, et al, Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24162737/)

[Sawcer S, et al, Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011)](https://pubmed.ncbi.nlm.nih.gov/21833088/)

[McQuade A, et al, Gene expression and functional deficits underlie TREM2 and HLA-DRB1 effects in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27294511/)

[Wang Y, et al, TREM2-mediated microglial autophagy in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26317468/)

[Hamza TH, et al, HLA-DRB1*04 alleles protect against Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20930117/)

[Shi H, et al, HLA-DRB1 alleles and Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24739668/)

[Karch CM, et al, Novel late-onset Alzheimer disease loci (2012)](https://pubmed.ncbi.nlm.nih.gov/22941636/)

[Yokoyama JS, et al, System-level analysis of brain structure and function in HLA-DRB1 (2016)](https://pubmed.ncbi.nlm.nih.gov/26853300/)

[Lue LF, et al, Microglial activation in Alzheimer disease (2001)](https://pubmed.ncbi.nlm.nih.gov/11487047/)

[Sedel F, et al, CSF HLA-DRB1 and neuroinflammation (2016)](https://pubmed.ncbi.nlm.nih.gov/26944276/)

📖 View canonical wiki page →

HLA-DRB1 Protein

HLA-DRB1 Protein

Introduction

Overview

HLA-DRB1 Protein

Introduction

Overview

Protein Information

Structure

Normal Function

Expression Pattern

Role in Disease

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Molecular Mechanisms

Therapeutic Targeting

Animal Models

Research Directions

Key Publications

See Also

External Links

Background

References